Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase

By Sica Domenic  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 825-837

Adis International

Access to resources Recommend Favorite

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease: Results of a 52-Week Open-Label Study

By Edwards Keith  

Clinical Drug Investigation, Vol. 25, Iss. 8, 2005-01 ,pp. : 507-515

Adis International

Access to resources Recommend Favorite

Long-Term Efficacy and Tolerability of a Fixed-Dose Combination of Antihypertensive Agents: An Open-Label Surveillance Study in China

By Wu Yiqun   Hu Yonghua   Tang Xun   He Liu   Ren Tao   Tao Qiushan   Qin Xueying   Sun Ningling  

Clinical Drug Investigation, Vol. 31, Iss. 11, 2011-11 ,pp. : 769-777

Adis International

Access to resources Recommend Favorite

Effects of Structured Follow-Up and of More Effective Acid Inhibitory Treatment in the Management of GORD Patients in a Swedish Primary-Care Setting: A Randomized, Open-Label Study

By Ekesbo Rickard  

Clinical Drug Investigation, Vol. 31, Iss. 3, 2011-03 ,pp. : 181-189

Adis International

Access to resources Recommend Favorite

An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients

By Ersoy Mehmet A.   Noyan Aysin M.   Elbi Hayriye  

Clinical Drug Investigation, Vol. 28, Iss. 2, 2008-01 ,pp. : 113-120

Adis International

Access to resources Recommend Favorite